Loading…

GE Healthcare acquired France-based Zionexa to develop and commercialize molecular imaging agents for cancer treatment, including Cerianna.
“This acquisition further demonstrates our commitment to enabling precision health and providing innovations that support oncologists, nuclear medicine specialists and other physicians throughout a cancer patient’s journey.”medicaldevice-network.com
Summarized from public sources; check the original articles before acting on it.